Cannabinoids Clinical Trials Medicine Patients 
NORML
MAY 26, 2020
The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinical trial data published in the European Journal of Pain. Additional information regarding cannabinoids and pain appears online h ere.
Puff Puff Post
MARCH 10, 2020
InMed has conducted preclinical pharmacology studies that suggest CBN in INM-755 may help relieve hallmark EB symptoms, including inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients. For more information, visit www.inmedpharma.com.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Cannigma
MARCH 18, 2021
Published in Nature Partner Journals and sponsored by the Parkinson’s Foundation, the study found that nearly 25% of Parkinson’s patients had used cannabis in the past six months, but that one in four of that group did not know what type or form of cannabis they used, and nearly half did not know their dosage. Of the 43.9% Shutterstock).
Veriheal
MAY 26, 2022
But one area of cannabis medicine is still lagging behind—research. Patients around the world are in need of natural, alternative medical solutions, and Realm of Caring (RoC) is on a mission to serve them. RoC also works to increase patients’ access to medical cannabis by helping U.S. Bringing Cannabis Into Mainstream Medicine.
The Cannigma
FEBRUARY 2, 2021
In a new survey of German patients with Parkinson’s disease, 8% of patients reported using cannabis products. Of these consumers, over half said the drug had a beneficial clinical effect on their condition. Patients can also access CBD products without a prescription through local pharmacies.
Otherside Farms
JANUARY 24, 2019
In San Francisco and New York City, the physician-led pediatric studies will assess the viability of a purified cannabidiol as an anti-seizure treatment among patients with various forms of epilepsy. Although both studies will enroll 25 patients initially, the U.S.
Cannabis Law Report
OCTOBER 6, 2021
Flora will conduct thorough due diligence and honor the traditional FDA and NHS route in scientific processes to ensure consistency, quality, and delivery of cannabinoids for specific disease conditions, backed by data, with an initial focus on fibromyalgia, brain health, pain, and related research.
Expert insights. Personalized for you.
253 
Let's personalize your content